Cargando…

Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis

The objective of this work was to formulate co-loaded bilayer tablets containing ezetimibe (EZB) and atorvastatin (ATC). ATC loaded in the immediate-release (IR) layer is an HMG CoA reductase inhibitor, while EZB, added in the sustained-release (SR) layer, is a lipid-lowering agent. This study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mubeen, Iqra, Zaman, Muhammad, Farooq, Muhammad, Mehmood, Asim, Azeez, Fahad Khan, Rehman, Wajiha, Akhtar, Sohail, Chaudhry, Mueen Ahmad, Butt, Muhammad Hammad, Shamim, Qurat-ul-ain, Adnan, Sherjeel, Khan, Muhammad Rizwan, Atta-ur-Rehman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506081/
https://www.ncbi.nlm.nih.gov/pubmed/36145914
http://dx.doi.org/10.3390/polym14183770
_version_ 1784796633840484352
author Mubeen, Iqra
Zaman, Muhammad
Farooq, Muhammad
Mehmood, Asim
Azeez, Fahad Khan
Rehman, Wajiha
Akhtar, Sohail
Chaudhry, Mueen Ahmad
Butt, Muhammad Hammad
Shamim, Qurat-ul-ain
Adnan, Sherjeel
Khan, Muhammad Rizwan
Atta-ur-Rehman,
author_facet Mubeen, Iqra
Zaman, Muhammad
Farooq, Muhammad
Mehmood, Asim
Azeez, Fahad Khan
Rehman, Wajiha
Akhtar, Sohail
Chaudhry, Mueen Ahmad
Butt, Muhammad Hammad
Shamim, Qurat-ul-ain
Adnan, Sherjeel
Khan, Muhammad Rizwan
Atta-ur-Rehman,
author_sort Mubeen, Iqra
collection PubMed
description The objective of this work was to formulate co-loaded bilayer tablets containing ezetimibe (EZB) and atorvastatin (ATC). ATC loaded in the immediate-release (IR) layer is an HMG CoA reductase inhibitor, while EZB, added in the sustained-release (SR) layer, is a lipid-lowering agent. This study was conducted to evaluate the effects of polymer on the formulation and characterization of bilayer tablets, as well as the therapeutic impact of the concurrent use of both drugs having a sequential release pattern. To obtain the optimized results, four different formulations with variable compositions were developed and evaluated for different parameters. The drug release studies were carried out using a type II dissolution apparatus, using phosphate buffer solution (PBS) of 1.2 pH for IR of EZB for an initial 2 h, followed by 24 h studies for ATC in PBS 6.8 pH. The IR layer showed rapid drug release (96%) in 2 h, while 80% of the ATC was released in 24 h from the SR layer. Locally obtained, 6-week-old female albino rats were selected for in vivo studies. Both preventive and curative models were applied to check the effects of the drug combination on the lipid profile, atherosclerosis and physiology of different organs. Studies have shown that the administration of both drugs with different release patterns has a better therapeutic effect (p < 0.05), both in preventing and in curing hyperlipidemia. Conclusively, through the sequential release of ATC and EZB, a better therapeutic response could be obtained.
format Online
Article
Text
id pubmed-9506081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95060812022-09-24 Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis Mubeen, Iqra Zaman, Muhammad Farooq, Muhammad Mehmood, Asim Azeez, Fahad Khan Rehman, Wajiha Akhtar, Sohail Chaudhry, Mueen Ahmad Butt, Muhammad Hammad Shamim, Qurat-ul-ain Adnan, Sherjeel Khan, Muhammad Rizwan Atta-ur-Rehman, Polymers (Basel) Article The objective of this work was to formulate co-loaded bilayer tablets containing ezetimibe (EZB) and atorvastatin (ATC). ATC loaded in the immediate-release (IR) layer is an HMG CoA reductase inhibitor, while EZB, added in the sustained-release (SR) layer, is a lipid-lowering agent. This study was conducted to evaluate the effects of polymer on the formulation and characterization of bilayer tablets, as well as the therapeutic impact of the concurrent use of both drugs having a sequential release pattern. To obtain the optimized results, four different formulations with variable compositions were developed and evaluated for different parameters. The drug release studies were carried out using a type II dissolution apparatus, using phosphate buffer solution (PBS) of 1.2 pH for IR of EZB for an initial 2 h, followed by 24 h studies for ATC in PBS 6.8 pH. The IR layer showed rapid drug release (96%) in 2 h, while 80% of the ATC was released in 24 h from the SR layer. Locally obtained, 6-week-old female albino rats were selected for in vivo studies. Both preventive and curative models were applied to check the effects of the drug combination on the lipid profile, atherosclerosis and physiology of different organs. Studies have shown that the administration of both drugs with different release patterns has a better therapeutic effect (p < 0.05), both in preventing and in curing hyperlipidemia. Conclusively, through the sequential release of ATC and EZB, a better therapeutic response could be obtained. MDPI 2022-09-09 /pmc/articles/PMC9506081/ /pubmed/36145914 http://dx.doi.org/10.3390/polym14183770 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mubeen, Iqra
Zaman, Muhammad
Farooq, Muhammad
Mehmood, Asim
Azeez, Fahad Khan
Rehman, Wajiha
Akhtar, Sohail
Chaudhry, Mueen Ahmad
Butt, Muhammad Hammad
Shamim, Qurat-ul-ain
Adnan, Sherjeel
Khan, Muhammad Rizwan
Atta-ur-Rehman,
Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
title Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
title_full Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
title_fullStr Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
title_full_unstemmed Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
title_short Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
title_sort formulation of modified-release bilayer tablets of atorvastatin and ezetimibe: an in-vitro and in-vivo analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506081/
https://www.ncbi.nlm.nih.gov/pubmed/36145914
http://dx.doi.org/10.3390/polym14183770
work_keys_str_mv AT mubeeniqra formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT zamanmuhammad formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT farooqmuhammad formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT mehmoodasim formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT azeezfahadkhan formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT rehmanwajiha formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT akhtarsohail formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT chaudhrymueenahmad formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT buttmuhammadhammad formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT shamimquratulain formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT adnansherjeel formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT khanmuhammadrizwan formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis
AT attaurrehman formulationofmodifiedreleasebilayertabletsofatorvastatinandezetimibeaninvitroandinvivoanalysis